iPSC-Derived Erythroid Lineages for Expansion and Enucleation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methodologies for generating red blood cells from induced pluripotent stem cells (iPSCs) are inadequate due to constraints in expansion of erythrocyte lineage cells or insufficient enucleation, leading to a national blood crisis and difficulties in blood transfusion management.
Innovation Solution
A method involving the differentiation of iPSCs to embryoid bodies, enrichment for CD34+ cells, and induction of endothelial-to-hematopoietic transition (EHT) to produce gene-edited hematopoietic stem cells (HSCs) with a hyperresponsive Erythropoietin Receptor, followed by erythroid lineage differentiation, which includes culturing under specific conditions to yield enucleated erythrocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methodologies are used to generate RBCs from iPSCs, then the process can be performed, but expansion of erythrocyte lineage cells is constrained and enucleation is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying culture conditions including oxygen tension (switching from ambient to controlled oxygen levels), growth factor concentrations (EPO, SCF, TPO), and media composition to optimize both expansion and enucleation. These parameter adjustments enable simultaneous improvement of productivity and reliability
Solution Approach 2:
The protocol employs periodic action through staged differentiation where cells progress through defined time points (e.g., days 0-14 for HSC generation, days 14-28 for erythroid differentiation). This periodic progression through distinct developmental stages enables controlled expansion followed by controlled enucleation, resolving the contradiction between maintaining cell numbers and achieving complete enucleation
2Adaptability or versatility
If iPSCs are differentiated to produce HSCs through EHT, then hematopoietic lineage can be generated, but the process complexity increases
Solution Approach 1:
The patent segments the differentiation process into distinct modular stages: (1) iPSC to embryoid body formation, (2) EHT induction to generate HSCs, (3) HSC expansion, and (4) Erythroid lineage differentiation. This segmentation allows each stage to be optimized independently, managing overall complexity while maintaining versatility
Solution Approach 2:
The protocol achieves universality by using a single differentiated iPSC platform to generate multiple hematopoietic lineages including HSCs, erythroid progenitors, and potentially other blood cell types. This multi-functional capability is achieved through sequential differentiation cues rather than separate protocols, improving adaptability while controlling complexity
3Reliability
If gene editing is applied to create HLA-matched cells, then compatibility with patients is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by performing gene editing on iPSCs before differentiation to HSCs and subsequent expansion. This timing allows genetic modifications (such as HLA allele corrections or knockouts) to be established early when cells are still pluripotent and易于 manipulate, simplifying the overall process compared to editing after differentiation
Solution Approach 2:
The protocol uses copying by creating isogenic cell lines with specific HLA alleles through gene editing, then expanding these cloned lines to generate patient-matched products. This copying approach ensures genetic consistency and compatibility while managing complexity through standardized editing protocols
4Productivity
If ex vivo production is implemented, then blood transfusion needs can be met, but the scale-up difficulty increases
Solution Approach 1:
The patent applies self-service by designing a fully ex vivo system where iPSCs autonomously differentiate through defined stages without requiring in vivo host factors. The protocol uses self-contained culture systems with defined media and growth factors, enabling scalable manufacturing while meeting blood product needs
Solution Approach 2:
The protocol manages scale-up complexity through parameter changes in culture conditions, including oxygen tension, growth factor concentrations, and media compositions that can be standardized and scaled. These controlled parameter adjustments enable transition from research-scale to manufacturing-scale production while maintaining productivity
Data Source
AI summary
The present disclosure, in various aspects and embodiments, provides methods for generating hematopoietic lineages for cell therapy, including erythroid progenitor cells, progenitor erythroblasts, granulocyte-macrophage progenitor cells (GMPs), and megakaryocyte erythroid progenitor cells (MEPs), and erythroid cells. In various embodiments, the invention provides for efficient ex vivo processes for developing such hematopoietic lineages, including but not limited to progenitor erythroblast cells and erythroblast cell lineages, from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or bone marrow. The present invention also provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.